Sifting through countless of stocks in the Biotechnology industry can be tedious, and sometimes two stocks are just too similar to judge which is the better investment. If you’re on the fence about investing in Gilead Sciences, Inc., Bayer Aktiengesellschaft or Bayer Aktiengesellschaft because you’re not sure how they measure up, it’s important to compare them on a few factors before making your decision.

Read on to learn how Gilead Sciences, Inc., Bayer Aktiengesellschaft and Bayer Aktiengesellschaft compare based on key financial metrics to determine which better meets your investment needs.

About Gilead Sciences, Inc., Bayer Aktiengesellschaft and Bayer Aktiengesellschaft

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Descovy, Genvoya, Odefsey, Sunlenca, Symtuza, and YeztugoFor the treatment of HIV-1 infection in patients. It also provides Epclusa, Livdelzi, and Vemlidy to treat chronic hepatitis C virus, primary biliary cholangitis, and chronic hepatitis B virus; Tecartus, a T-cell therapy for the treatment of adult patients; Trodelvy, an injection for intravenous use; and Yescarta, a suspension for intravenous infusion, is a CAR T-cell therapy for the treatment of adult patients. Further, it provides AmBisome, for the treatment of serious invasive fungal infections; and Veklury for the treatment of COVID-19. Additionally, the company engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company has collaboration agreements with Shenzhen Pregene Biopharma Co., Ltd.; Abingworth; Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Bayer Aktiengesellschaft operates as a life science company in Europe, the Middle East, Africa, Germany, Switzerland, North America, the United States, the Asia Pacific, China, Latin America, and Brazil. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment provides prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents, as well as cell and gene therapy. The Consumer Health segment offers nonprescription over-the-counter medicines for self-medication and self-care; nutritional supplements; allergy, cough, and cold; dermatology; pain and cardiovascular risk prevention; and digestive health products. The Crop Science segment offers chemical and biological crop protection products, improved plant traits, seeds, digital solutions, and pest and weed management products, as well as customer services for agriculture. It also engages in the breeding, propagation, and production/processing of seeds, including seed dressing. The company distributes its products through wholesalers, pharmacies and pharmacy chains, supermarkets, online and other retailers, and hospitals, as well as directly to farmers. Bayer Aktiengesellschaft has a strategic alliance with The University of Colorado Anschutz, along with UCHealth and Children's Hospital Colorado to advance drug development and clinical trials. Bayer Aktiengesellschaft has a strategic alliance Henry Ford Health. Bayer Aktiengesellschaft was founded in 1863 and is based in Leverkusen, Germany.

Latest Biotechnology and Gilead Sciences, Inc., Bayer Aktiengesellschaft Stock News

As of September 2, 2026, Gilead Sciences, Inc. had a $185.5 billion market capitalization, compared to the Biotechnology median of $288.9 million. Gilead Sciences, Inc.’s stock is up 23.2% in 2026, up 1.6% in the previous five trading days and up 32.74% in the past year.

Currently, Gilead Sciences, Inc. does not have a price-earnings ratio. Gilead Sciences, Inc.’s trailing 12-month revenue is $30.5 billion with a -10.6% net profit margin. Year-over-year quarterly sales growth most recently was 10.2%. Analysts expect adjusted earnings to reach $-0.431 per share for the current fiscal year. Gilead Sciences, Inc. currently has a 2.2% dividend yield.

As of September 2, 2026, Bayer Aktiengesellschaft had a $56.0 billion market cap, putting it in the 94th percentile of all stocks. Bayer Aktiengesellschaft’s stock is up 32.6% in 2026, up 1.7% in the previous five trading days and up 77.75% in the past year.

Currently, Bayer Aktiengesellschaft does not have a price-earnings ratio. Bayer Aktiengesellschaft’s trailing 12-month revenue is $51.8 billion with a -3.8% net profit margin. As of September 2, 2026, Bayer Aktiengesellschaft has not reported significant year-over-year quarterly sales. Analysts expect adjusted earnings to reach $1.297 per share for the current fiscal year. Bayer Aktiengesellschaft does not currently pay a dividend.

How We Compare Gilead Sciences, Inc., Bayer Aktiengesellschaft and Bayer Aktiengesellschaft Stock Grades

Stock evaluation requires access to huge amounts of data and the knowledge and time to sift through it all, make sense of financial ratios, read income statements and analyze recent stock movements. AAII created A+ Investor, a robust data suite that condenses data research in an actionable and customizable way suitable for investors of all knowledge levels, to help investors streamline and work through such data.

AAII’s proprietary stock grades come with A+ Investor. These offer intuitive A‐F grades for each of five key investing factors: value, growth, momentum, earnings estimate revisions and quality. Here, we’ll take a closer look at Gilead Sciences, Inc., Bayer Aktiengesellschaft and Bayer Aktiengesellschaft’s stock grades to see how they measure up against one another.

Learn more about A+ Investor here!

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

Gilead Sciences, Inc., Bayer Aktiengesellschaft and Bayer Aktiengesellschaft Stock Value Grades

Company	Ticker	Value
Gilead Sciences, Inc.	GILD	D
Bayer Aktiengesellschaft	BAYRY	na
Bayer Aktiengesellschaft	BAYRY	na

Successful stock investing involves buying low and selling high, so stock valuation is an important consideration for stock selection.

Buying stocks that are going to go up typically means buying stocks that are undervalued in the first place, although momentum investors may argue that point.

AAII’s A+ Investor Value Grade derives from a stock’s value score. The Value Score is the percentile rank of the average of the percentile ranks of the price-to-sales ratio, price-earnings ratio, enterprise-value-to-EBITDA (EV/EBITDA) ratio, shareholder yield, price-to-book-value ratio and price-to-free-cash-flow ratio. The score is variable, meaning it can consider all six ratios or, should any of the six ratios not be valid, the remaining ratios that are valid. To be assigned a Value Score, stocks must have a valid (non-null) ratio and corresponding ranking for at least two of the six valuation ratios.

Stocks with a Value Score from 81 to 100 are considered deep value, those with a score between 61 and 80 are a good value and so on.

Gilead Sciences, Inc. has a Value Score of 28, which is Expensive. Bayer Aktiengesellschaft does not have a meaningful Value Score. Bayer Aktiengesellschaft does not have a meaningful Value Score.

The Value Stock Winner: No Clear Winner

Neither Gilead Sciences, Inc., Bayer Aktiengesellschaft or Bayer Aktiengesellschaft has a high enough value grade to be considered a “winner.” Investors who are considering these companies should do additional due diligence and research to see if either could be a good addition to their portfolio. It’s important to look at a wide range of financial metrics in order to determine if Gilead Sciences, Inc., Bayer Aktiengesellschaft or Bayer Aktiengesellschaft is the better investment when it comes to value.

Gilead Sciences, Inc., Bayer Aktiengesellschaft and Bayer Aktiengesellschaft’s Momentum Grades

Company	Ticker	Momentum
Gilead Sciences, Inc.	GILD	B
Bayer Aktiengesellschaft	BAYRY	A
Bayer Aktiengesellschaft	BAYRY	A

Momentum grades help to uncover stocks experiencing anomalously high rates of return; research finds that stocks with high relative levels of momentum tend to outperform, whereas those with low levels of momentum tend to continue underperforming. Momentum is based on the price change of a stock over a specified period relative to all other stocks.

Typically, AAII looks at the weighted relative strength over the trailing four quarters. The weighted four-quarter relative strength rank is the relative price change for each of the past four quarters. The most recent quarterly price change is given a weight of 40% and each of the three previous quarters are given a weighting of 20%.

Gilead Sciences, Inc. has a Momentum Score of 72, which is Strong. Bayer Aktiengesellschaft has a Momentum Score of 90, which is Very Strong. Bayer Aktiengesellschaft has a Momentum Score of 90, which is Very Strong.

The Momentum Grade Winner: Bayer Aktiengesellschaft

As you can clearly see from the Momentum Grade breakdown above, Bayer Aktiengesellschaft is considered to have stronger momentum compared to Gilead Sciences, Inc.. For those specifically looking for companies that have stronger momentum compared to other companies in the same industry, Bayer Aktiengesellschaft could be a good stock to invest in. However, it’s important for investors to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Gilead Sciences, Inc., Bayer Aktiengesellschaft and Bayer Aktiengesellschaft’s Estimate Revisions Grades

Company	Ticker	Earnings Estimate
Gilead Sciences, Inc.	GILD	B
Bayer Aktiengesellschaft	BAYRY	F
Bayer Aktiengesellschaft	BAYRY	F

Earnings estimate revisions scores consider the magnitude of a company’s earnings surprise in its last two reported fiscal quarters. Often, positive surprises beget further positive surprises‐or at least continued sales growth (the exact opposite is generally true, too).

Estimate revisions offer an indication of what analysts are thinking about the short-term prospects of a firm. Estimate revisions are based on the statistical significance of a firm’s last two quarterly earnings surprises and the percentage change in its consensus estimate for the current fiscal year over the past month and past three months.

Gilead Sciences, Inc. has a Earnings Estimate Score of 75, which is Positive. Bayer Aktiengesellschaft has a Earnings Estimate Score of 5, which is Very Negative. Bayer Aktiengesellschaft has a Earnings Estimate Score of 5, which is Very Negative.

The Earnings Estimate Revisions Grade Winner: Gilead Sciences, Inc.

As you can clearly see from the Earnings Estimate Revisions Grade breakdown above, Gilead Sciences, Inc. has a better Earnings Estimate Revisions Grade than Bayer Aktiengesellschaft. For those who are specifically looking for companies with better short-term prospects when compared to other companies in the same industry, Gilead Sciences, Inc. could be a good stock to invest in. However, it’s important to analyze multiple factors based on a wide range of metrics before deciding whether to buy.

Other Gilead Sciences, Inc., Bayer Aktiengesellschaft and Bayer Aktiengesellschaft Grades

In addition to Momentum, Estimate Revisions and Value, A+ Investor also provides grades for Growth and Quality.

Growth investing builds on the idea that stocks of companies exhibiting strong, consistent and prolonged growth outperform those of slower-growth companies. AAII measures growth through consistency of annual sales growth, five-year sales growth rankings adjusted for extreme levels, and consistency of positive annual cash from operations.

AAII’s A+ Investor Quality Grade comes from the ranking of key metrics. Specifically, the quality grade is the percentile rank of the composite of return on assets (ROA), return on invested capital (ROIC), gross profit relative to assets, buyback yield, change in total liabilities to assets, accruals, Z double prime bankruptcy risk (Z) score and F-Score.

These 2 key factors, when combined with the above, provide a holistic view into a particular stock. Further, by joining A+ Investor you can see whether Gilead Sciences, Inc., Bayer Aktiengesellschaft and Bayer Aktiengesellschaft pass any of our 60+ stock screens that have outperformed the market since their creation.

So, Which Is the Better Investment, Gilead Sciences, Inc., Bayer Aktiengesellschaft or Bayer Aktiengesellschaft Stock?

Overall, Gilead Sciences, Inc. stock has a Value Score of 28, Momentum Score of 72 and Estimate Revisions Score of 75.

Bayer Aktiengesellschaft stock has a Value Score of , Momentum Score of 90 and Estimate Revisions Score of 5.

Bayer Aktiengesellschaft stock has a Value Score of , Momentum Score of 90 and Estimate Revisions Score of 5.

Comparing Gilead Sciences, Inc., Bayer Aktiengesellschaft and Bayer Aktiengesellschaft’s grades, scores and metrics can act as a solid basis to determine whether they may be a good investment or not. You’ll also want to look at your portfolio’s asset allocation as well as your risk tolerance and financial goals to see if either of these stocks would make a good fit for you. AAII can help you figure out which investments align with your individual needs and preferences.

Investors are encouraged to do their own due diligence and research. In this way, individuals can effectively become managers of their own assets‐without having to rely on others for financial independence. You can count on AAII for timeless articles on financial planning and stock-picking, unbiased research and actionable analysis.

A+ Investor adds to our qualitative teaching with a powerful data suite to help you whittle down investment choices to find stocks, exchange-traded funds (ETFs) or mutual funds that meet your needs.

AAII Disclaimer

We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown, because past, hypothetical or simulated performance is not necessarily indicative of future results. Before making an investment decision, you should consider your circumstances and whether the information on our content is applicable to your situation. This information was prepared in good faith, and we accept no liability for any errors or omissions. The full disclaimer can be read here.